Gpixel Changchun Microelectronics Inc. announced the formal launch of its Hong Kong initial public offering, comprising 65.29 million H shares—subject to a 15% over-allotment option—at an offer price of HK$39.88 each.

Key terms of the Global Offering • Share mix: 6.53 million shares (10%) allocated to the Hong Kong Public Offering and 58.76 million shares (90%) to the International Offering, both subject to reallocation. • Over-allotment option: International underwriters may require issuance of up to 9.79 million additional shares within 30 days after the close of the public offer, equivalent to 15.0% of the initial deal size. • Market stabilization: CLSA Limited, acting as stabilizing manager, may conduct price-support transactions until 14 May 2026.

Application and timetable • Public subscription opens 9 April 2026 at 9:00 a.m. and closes 14 April 2026 at 12:00 noon (Hong Kong time) via a fully electronic process (HK eIPO White Form or HKSCC EIPO). • Allocation results and basis of allotment will be published by 11:00 p.m. on 16 April 2026. • Dealings in the H shares are scheduled to begin on the Hong Kong Stock Exchange at 9:00 a.m. on 17 April 2026 under the ticker 3277, trading in board lots of 100 shares.

Use of CCASS Subject to listing approval, the shares will be admitted to CCASS for clearing and settlement on the first trading day, with T+2 settlement applied to trades between Exchange participants.

Underwriting and termination clause CITIC Securities (Hong Kong) Limited and Guotai Junan Capital Limited act as joint sponsors; CLSA Limited and Guotai Junan Securities (Hong Kong) Limited serve as overall coordinators, global coordinators, joint bookrunners, and lead managers. The Hong Kong underwriting agreement may be terminated at any time before 8:00 a.m. on the listing date if specified events occur, as detailed in the prospectus.

Board composition As of the announcement date, the board consists of nine members: three executive directors (Dr. Wang Xinyang, Dr. Zhang Yanxia, Ms. Wu Qinyun), three non-executive directors (Ms. Yang Yi, Dr. Chu Hairong, Dr. Xiong Jingying), and three independent non-executive directors (Dr. Wang Xinlu, Dr. Xie Ning, Dr. Gao Teng).

All figures are drawn directly from the 9 April 2026 announcement and prospectus.